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Abstract—Adverse drug events (ADEs) are a serious health
problem that can be life-threatening. While a lot of studies
have been performed on detect correlation between a drug and
an AE, limited studies have been conducted on personalized
ADE risk prediction. Among treatment alternatives, avoiding
the drug that has high likelihood of causing severe AE can
help physicians to provide safer treatment to patients. Existing
work on personalized ADE risk prediction uses the information
obtained in the current medical visit. However, on the other hand,
medical history reveals each patients unique characteristics and
comprehensive medical information. The goal of this study is to
assess personalized ADE risks that a target drug may induce on
a target patient, based on patient medical history recorded in
claims codes, which provide information about diagnosis, drugs
taken, related medical supplies besides billing information. We
developed a HTNNR model (Hierarchical Time-aware Neural
Network for ADE Risk) that capture characteristics of claim
codes and their relationship. The empirical evaluation show
that the proposed HTNNR model substantially outperforms the
comparison methods, especially for rare drugs.
Index Terms—Adverse Drug Event, Neural Network, Claim
Code
I. INTRODUCTION
Adverse Drug Events (ADEs), defined as “an appreciably
harmful or unpleasant event resulting from the use or misuse
of a drug” [1], are a serious health problem that can be
life-threatening. According to FDA, the number of ADEs
reported to FAERS (FDA Adverse Event Reporting System)
resulting in death and serious outcomes increase consistently
[2], [3]. Statistics [4] show each year ADEs account for over
3.5 million physician office visits, an estimated 1 million
emergency department visits, and approximately 125,000 hos-
pital admissions. For inpatient setting, ADEs account for an
estimated 1 in 3 of all hospital adverse events (AE) and affect
about 2 million hospital stays each year.
While pre-marketing review is conducted before any drugs
are approved for marketing, it is insufficient for identifying all
the potential ADEs due to the limited sample size and duration
of clinical trials. Post-marketing surveillance is critical for
identifying ADRs. Although patient can report ADE through
voluntary and spontaneous report systems, such as FDA
FAERS, the median under-reporting rate across 37 studies
using a wide variety of post-marketing surveillance methods
from 12 countries is 94% according to an earlier study [5].
There are increasing interests of using large-scale longitu-
dinal clinical data, EHRs, associated clinical notes, as well
as claims data, for studying ADEs. Such data contain rich
and accurate information about patients health status, their
treatment plan and clinical outcomes. Since such data is
generated as part of medical practices, without relying on
patient self-reporting, it is available in large-scale with high
quality.
The studies can be categorized into two types: ADE de-
tection and personalized ADE risk prediction. The goal of
ADE detection is to identify the correlation or causal rela-
tionship between a target drug and an observed AE. Some
use statistic methods such as the disproportionality analysis
[6]–[8], others use machine learning methods such as support
vector machines, random forests and neural networks [9], [10].
Besides detecting drug-AE correlation on the whole patient
population, there are also studies on ADE risk stratification
which assesses the correlation on patient populations defined
by their demographics [11].
In contrast of ADE detection for population, the studies
on personalized ADE risk prediction assess the likelihood of
individuals to experience an AE based on individual character-
istics and clinical history. Indeed different patient may have
different AE outcomes even taking the same drug. Among
alternative drugs for treatment, avoiding the one that has high
likelihood of causing severe AE can help physicians to provide
safer treatment to patients, as a form of personalized treatment.
There are only a few works addressing the problem [12],
[13]. They take as input patient demographic information and
clinical information of the current hospital visit.
What is lacking in the literature is to consider patient
medical history in addition to the current visit information to
make personalized prediction for ADE risks. Medical history
better reveals each patient’s unique characteristics, as well as
the drugs and treatments taken in the past, which may interact
with the current treatment to induce AE [14], [15].
However, patient medical history data is often not readily
available and is difficult to process. First, patient may be seen
at multiple healthcare centers that do not share patient data
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in their EHR system. Second, patient self-reporting medical
history may not be accurate or comprehensive. Furthermore,
processing large-scale longitudinal medical history data, which
contains diverse type of clinic information, poses technical
complexity
The goal of this study is to assess personalized ADE risks
that a target drug may induce on a target patient, based on
patient medical history recorded in claims, which we acquired
access via collaboration with Inovalon, a healthcare analytics
company. Our findings can be used by Medicare/Medicaid and
health insurance company to provide assistance to healthcare
professionals to identify safe treatment plan.
Claims data provide valuable information about patients.
It contains the information about diagnoses, drugs taken,
related medical supplies, treatment procedures, besides billing
information, for each patient encounter. While a patient may
receive healthcare from multiple providers, and have their
medical information scattered in multiple EHR systems, claims
data effectively records a patients interactions across different
healthcare systems and thus provides longitudinal and accurate
data in the continuum of a patient’s health care history [16].
However, there are several technical challenges that must be
addressed. The first challenge is how to capture the “mean-
ings” of claim codes. There are over 64K unique claims code
in the data, belong to nine different types. We make an analogy
between claim codes and words, and between claim history
and documents. Then we propose to use word embedding
methods in Natural Language Processing (NLP) to generate
embedding for claim codes, so that claim codes that are used
in similar ways are represented with similar vectors, naturally
capturing their meanings.
The second challenge is how to model patient medical claim
history. A patient’s claim history consists of encounters and
each encounter consists of claim codes. The relationship of
claim codes within an encounter is different from that of claim
codes in different encounters. This present a unique challenge,
as exiting work does not consider patient’s medical history
but only the current medical visit. To model patient’s claim
history, we propose a HTNNR model stands for Hierarchical
Time-aware Neural Network with drug-code Representation.
The first layer neural network encodes claim codes within an
encounter into vectors, and the second layer neural network
represents the claim history with a sequence of encounters
into vectors. Then we propose to use a bi-directional neural
network model to capture the un-ordered relationship among
claim codes within an encounter. We further propose to use
time-aware deep learning model to capture not only the se-
quential but also the temporal relationship among encounters.
The contributions of our work include the following. First,
to the best of our knowledge, this the first study that uses
patient claim history to make personalized prediction on drug-
induced ADE risks. Second, we have made several technical
contributions. We proposed claims code embedding, a hierar-
chical neural network model to capture patient claim history,
and drug-claim code representations. We also used different
neural network models for encounter representation and for
claim history representations. Finally, extensive evaluation on
about 500k patients demonstrates effective prediction perfor-
mance and high efficiency of our proposed approach.
The rest of the paper is organized as follows. Section II
discusses the related work. Section III presents the problem
statement and data overview. Section IV and Section V
presents the two methods for patient ADE risk prediction.
Experimental results are presented in Section VI. Section VII
concludes the paper.
II. RELATED WORK
Studies on ADEs can be categorized into ADE detection on
population, personalized AE risk prediction, and prediction of
ADE outcome intensity (e.g. hospitalization and mortality).
The goal of ADE detection is to identify the correlation or
causal relationship between a target drug and an observed AE,
using statistical methods or machine learning methods. Some
studies applied association rule mining methods for ADE
detection [17], [18]. Disproportionality analysis are widely
used for ADE detection from various data sources, such as
EHR data [19], [20], clinic notes [8], and clinical trials [21].
Disproportionality analysis is based on the contrast between
observed and expected numbers of co-occurrences, for any
given combination of drug and AE, to detect possible causal
relations between drugs and AEs. It, however, does not con-
sider context features, which are rich in unstructured clinical
notes. Various Natural Language Processing (NLP) and ma-
chine learning techniques have been applied on clinic notes
to detect drug-AE association, using expert-labeled ground
truth. [9], [10] extract multiple features like drug and AE
frequency and co-mention frequency from clinical notes and
use machine learning methods like support vector machine and
random forest to detect drug-AE correlation. [22], [23] start
with a named entity recognition module based on Conditional
Random Fields to extract medical entities relevant to ADEs
from clinical notes, and then use random forest and neural
networks, respectively, as the relation classification model.
Little has been studied on using claims data for ADE detection.
[24] use ICD codes and GPI drug code in claims data (see
Table I for description of the code) as input and design a
graph neural network model to construct a drug-disease graph
for ADE detection. They first embedded disease codes and
drug codes into a graph, respectively, then the merged drug
and disease graph is fed into a graph neural network for
ADE detection. They used the SIDER database as the ground
truth for ADEs. Besides detecting drug-AE correlation on the
whole patient population, there are also studies on ADE risk
stratification which assesses the drug-AE correlation on patient
populations defined by their demographics [11].
There are only a few studies in the category of personalized
AE risk prediction. Since AE risks of different patients are
different, even for the same drug, these studies make risk
predictions based on the individual patient’s characteristics
from clinical data. [13] develops a logistic regression model
to predict the risks of AEs of in-patients based on the patient
features and the medical conditions during this hospital stay.
TABLE I
DESCRIPTION OF DIFFERENT CLAIM CODES
Code Type Description
ICD International Statistical Classification of Diseases (ICD) codes capturing dis-
eases, symptoms, abnormal findings, complaints, etc. It includes diagnosis codes
(ICD10DX and ICD9DX) and procedure codes (ICD9PX and ICD10PX).
CPT report medical, surgical, and diagnostic procedures and services to entities such as
physicians, health insurance companies and accreditation organizations
POS Place of Service (POS) Codes are two-digit codes placed on health care professional
claims to indicate the setting in which a service was provided.
GPI The Generic Product Identifier (GPI) is a 14-character hierarchical classification
system that identifies drugs from their primary therapeutic use down to the unique
interchangeable product regardless of manufacturer or package size.
TOB Type of bill codes (TOB) identifies the type of bill being submitted to a payer. TOB
codes are four-digit alphanumeric codes that specify different pieces of information
on claim form
REVENUE Revenue Codes are descriptions and dollar amounts charged for hospital services
provided to a patient.
HCPCS The Healthcare Common Procedure Coding System (HCPCS) is a collection of codes
that represent procedures, supplies, products and services which may be provided
to Medicare beneficiaries and to individuals enrolled in private health insurance
programs.
DISCHARGE Identify where the patient is at the conclusion of a health care facility encounter (a
visit or an inpatient stay)
LOINC Logical Observation Identifiers Names and Codes (LOINC) is a database and
universal standard for identifying medical laboratory observations
They used multiple patient characteristics like gender and
age as features, also extracted some features from current
medical conditions like the number of medications and the
list of drugs taken. [12] takes clinical features as input, such
as ADE indication codes, primary diagnosis code and length
of the hospital stay to predict in-patient ADE risks. They
used multiple machine learning models like random forest
and support vector machines. Both make ADE risk prediction
based on the information of the current hospital stay. Being
most related to this category of studies, our work takes as input
a patient’s longitudinal medical history, not just the current
medical encounter. Also, we consider AE risks induced by
target drugs (perhaps due to interaction with other drugs or
medical conditions), whereas existing studies consider AE in
general. The dataset used in our studies is claims data.
Unlike studies on personalized AE risk prediction, which
predict the likelihood of a specific AE to occur, there are
also studies on predicting the likelihood of hospitalization
and mortality of a patient, due to outcomes of unspecified
AEs. Both of them are using the patient medical data from
FAERS. [25] proposed a hybrid model to predict the outcomes
of ADEs, based on patients demographic data, such as age
and gender, and drug-taken information, such as the route of
the drug intake and whether the adverse reaction subsided
when drug in-take was terminated. [26] developed a system
that takes patient demographics, drugs, relevant diseases in
pathology as input, and outputs ADE risk outcome assessment.
III. PROBLEM STATEMENT
In this section we present the data description and the
problem definition.
A. Data Description
The input data is medical claim history for a set of patients.
Each claim history is composed of a sequence of encounters,
and each encounter has a sequence of claim codes, as illus-
trated in Figure 3. At an encounter, a medical treatment and/or
evaluation and management services are provided. There are
nine different types of claim codes, which provide information
of medical diagnoses (ICD), procedures and services (CPT,
LOINC), setting where services are provided (POS), drug
information (GPI), billing (TOB, REVENUE, DISCHARGE),
and codes for Medicare and private health insurance program
users (HCPCS). Table I shows a description about these code
types.
The data used in empirical evaluation was provided by
Inolvaon, a technology company providing cloud-based plat-
forms empowering data-driven healthcare. It contains the
claims data of 500k patients for a duration of 2015-2019.
There are 64,070 unique claim codes. Figure 2 shows the
distribution of the number of encounters a patient has. We
can see that most patient has less than 500 encounters, and
the average number of encounters per patient is 158.7. The
average number of claim codes per patient is 1052 and the
average number of claim code per encounter is 6.6. Figure 1
shows the number of claim code occurrences of each category.
Fig. 1. Distribution of Claim Code Occurrences
Fig. 2. Distribution of Number of Encounters Per Patient
B. Problem Definition
Now we formally define the problem.
We model the problem as a classification task. A patient’s
claim history is composed of a sequence of encounters,
denoted as P = {e1, e2, . . . }. Each encounter ei is composed
of a sequence of claim codes, ei = {x1, x2, . . . }. Consider
a list of target ADEs, and a target drug d. y ∈ {−1, 1}
is the classification label, where y = 1 indicates that drug
d induced at least one ADE in the target ADE list on this
patient, and otherwise y = −1. For a set of patients who took
drug d, their claim histories before taking d along with their
corresponding labels are used to train the classification model.
For a target patient who has not taken drug d, the model takes
his claim history so far to predict the label, i.e. whether he will
experience an ADE in the target ADE list if taking d now.
Identifying ADEs from Claim History. First, we identify
ADEs from claims code. Based on literature, an ADE can
be identified from the claim codes by concurrent presence of
selected diagnosis codes and selected indication codes [27].
Diagnosis codes are part of the ICD codes as shown in Table I.
An indication code is a special type of diagnosis code indicates
that a patient experienced an ADE [27], [28]. Following
existing work [28], we use four categories of indication codes
as shown in Table II and their corresponding ICD codes. For
example, ICD code “T46.9” represents “Other and unspecified
agents primarily affecting the cardiovascular system” is an
indication code, indicating an ADE related to cardiovascular
system. If a diagnosis code and an indication code co-occur in
an encounter, we consider an ADE occurs and the diagnosis
code gives the information of the AE. For example: if a
diagnosis code “I42.7” (Cardiomyopathy due to drugs and
other external agents) and “T46.9” both occurs in an encounter,
then “I42.7” represents an ADE.
The diagnosis codes (ICD codes) of the target ADEs and
the GPI code of the target drugs are input of the problem. We
consider that a target drug induces a target ADE experienced
by a patient if the ICD code corresponding to the target ADE
and one of the indication codes in Table II are found in the
same encounter within time period N after taking the drug,
but not found in the claim history before taking the drug,
Specifically, as illustrated in Figure 3, suppose a patient starts
to take a target drug from encounter eM+1. If there is no
target ADE found before encounter eM+1 but is recorded in
encounter eM ′ along with an indication code, and the time
duration between eM+1 and eM ′ is less than N , then we
consider the target drug induces this ADE. We can also use
other approaches to generate ground truth, such as human
labeling.
Note that it is possible that an ADE is a result of drug-drug
interaction [29]. In other words, some time multiple drugs
together induce to an ADE. For any of these drug is a target
drug, for this drug the corresponding claim sequence is labeled
positively.
Also, N is considered the effective time of a drug to cause
AE. Currently N is set to be 3 months for all the drugs.
Different values of N can be used for different drugs based
on the drug characteristics when the information becomes
available.
TABLE II
INDICATION CODES FOR ADVERSE DRUG EVENTS
Indication Category Description
A1 The ICD-10 code description in-
cludes the phrase ’induced by med-
ication/drug’
A2 The ICD-10 code description in-
cludes the phrase ’induced by med-
ication or other causes’
B1 The ICD-10 code description in-
cludes the phrase ’poisoning by
medication’.
B2 The ICD-10 code description in-
cludes the phrase ’poisoning by or
harmful use of medication or other
causes’
IV. FIRST ATTEMPT
Since patient’s medical claim history consists of a sequence
of claim codes which encode medical diagnoses, procedures
Encounter 1 Encounter M+1Encounter3Encounter 2 …… Encounter M’ ……
Observation Period: N  Claim History Period
A Patient With a Sequence of  Encounter Records
…… 
 2018/01/03  2018/01/10  2018/10/07
Target Drug 
Observed
ADE Observed
Date:
'POS-11', 'ICD10DX-I10', 'ICD10DX-E109', 
'ICD10DX-E782', 'CPT-99213'
Fig. 3. Claim History Illustration
and services conducted, drugs taken and so on. Intuitively, the
problem can be modeled as a sequence classification problem.
Figure 4 shows a system architecture. The input is the patient’s
medical claim history represented as a sequence of claim
codes.cThen each claim code is represented as an embedding
vector. A deep learning model, Long Short-Term Memory
(LSTM), is then used to learn the dependency between the
claim codes in order to make the prediction whether this
patient will experience a target ADE if taking a target drug.
...
'POS-11', 'ICD10DX-I10', 'CPT-99213',…,  'CPT-92083', 'ICD10DX-H02831'
Sequence of 
claim codes
LSTM layer
Output layer
Claim code 
embedding layer
LSTM LSTM LSTMLSTM...
Fig. 4. The architecture of First Attempt Method
Claim Code Embedding. The claim code embedding layer
generates a vector for each claim code that captures the
characteristics of codes and the relationship among codes.
Word embedding is widely used in deep learning based NLP
techniques. Using dense and low-dimensional vectors to en-
code words bring computational benefits to downstream neural
network model processing. Learned based on word usage,
word embedding represents words that are used in similar
ways using similar vectors, naturally capturing their meaning.
We make the analogy that each claim code corresponds to a
word, an encounter corresponds to a sentence, and a patient
claims history corresponds to a document. The usage of claim
code indicate their correlation, just like the usage of words
in text. We use a popular word embedding method in NLP,
the skip-gram model [30]. It takes as input the collection
of all patient’s claim code sequences and generates a low
dimensional, continuous and real-value vector for each claim
code as its embedding.
Sequence Classification with LSTM. After using an em-
bedding to represent each claim code, the sequence of claim
code embedding is fed into a deep learning model to learn
the claim code dependencies. We identify all patients in the
training data who took a target drug. These patients’ sequences
of claim code embedding before taking the target drug, and
the corresponding labels of whether a target ADE is observed
within the L time period after taking the drug in the claim
history are used to train the model. The trained model then
predicts the label of each patient in the test data, based on
his/her claim code embedding sequence so far.
In contrast to Convolutional Neural Network (CNN), Re-
current Neural Networks (RNN) are designed for sequence
prediction problems 1. However, it suffers the problem of
gradient vanishing or exploding [31], where gradients may
grow or decay exponentially over long sequences. This makes
it difficult to model long-distance correlations in claim code
sequences. Recall that the average number of claim codes per
patient is 1052.
We proposed to use LSTM networks instead, which are
designed to overcome the vanishing gradient problem and to
efficiently learn long term dependencies. LSTMs accomplish
this by keeping an internal state that represents the memory
cell of the LSTM neuron. This internal state controls the
information flow through the cell state.
The new cell state cj and the output hj can be calculated
as:
cj = fj  cj−1 + Ij  tanh(Wc[Fj , hj−1] + bc) (1)
hj = oj  tanh(cj) (2)
where Ij , fj and oj denote input, forget and output gate,
respectively. Finally the output layer uses a softmax function
on the vector generated from the LSTM layer to make a
1The performance evaluation of CNN and and several feature-based ma-
chine learning methods are presented in Section VI.
prediction. This approach is referred as LSTM in the rest of
paper.
V. HTNNR MODEL
After presenting the LSTM method in Section IV, now we
discuss several characteristics of patient claim code history
and propose a novel model named as HTNNR Model stands
for Hierarchical Time-Aware Neural Network for ADE Risk.
A. A Hierarchical Neural Network
The LSTM method models patient claim history as a
sequence of claims code. However, this approach may not
accurately capture the relationship between the claims codes.
Recall that the claim history actually consists of a sequence of
encounters, each of which contains a sequence claim codes.
There are two observations. First, the number of claim codes
in different encounters can have big variation. For instance,
consider three encounters illustrated in Figure 3. The first
encounter represents a hospital stay, with 30 claim codes. The
next encounter represents a follow-up with a specialist, with
only four claim codes. The third encounter represents a visit to
a primary care doctor for a flu with another four claim codes.
The LSTM model ignores the encounter information, but just
considers the claim code sequence where code relationships
are reflected by their distances. In this example, the 1st code
and the 30-th code are considered less related since their
distance is 29, despite that they actually belong to the same
encounter. On the other hand, the 30-th code and the 35-th
one are considered as closely related since their distance is
only 5. However, they actually are two encounters apart, and
are not semantically closely related. The second observation
is that the claims code within an encounter are actually not
ordered, collectively describing an encounter event.
Based on this observation, we propose a hierarchical frame-
work to model the input data, as shown in Figure 5. The first
layer in framework generates a vector for each encounter,
called Encounter Representation. The second layer in the
framework takes the sequence of encounter vectors as input
and outputs an embedded vector for each patient’s claim
history, referred to as Claim History Representation. This
framework better captures the claim code relationships. Now
we discuss these two layers in term.
B. Encounter Representation
The Encounter Representation takes the patient claim his-
tory as input. It has two components: a Bi-LSTM layer and a
claim code attention layer. We discuss each in turn.
Bi-LSTM Representation for Encounters. Recall that the
LSTM method discussed in Section IV consider claim history
as a sequence of claim codes. However claim codes in an
encounter do not have sequential order, but are a set of codes
that collectively record an encounter event. Based on this
observation, we propose to use Bi-directional Long Short Term
Memory (Bi-LSTM) [32] to generate a representation of claim
codes in an encounter, which are unordered. Both previous
codes and following codes within an encounter are considered
by Bi-LSTM to model code dependencies. The output of the
jth claim code in an encounter is calculated as:
hj =
→
hj ⊕
←
hj , (3)
where ⊕ is an concatenation operation.
Claim Code Attention. Not all claim codes contribute equally
to the semantic representation of an encounter. Attention neu-
ral networks have recently demonstrated success in document
classification by learning the weights of words [33]. Hence,
we apply the attention mechanism to set weights of claim
codes, so that the model can focus on claim codes that
are important to capture the semantics of an encounter. The
encounter representation ve is formed by a weighted sum of
the vectors generated by Bi-LSTM.
E = tanh(H) (4)
α = softmax(wTE) (5)
ve = Hα
T (6)
Here H is a matrix consisting of vectors [h1, h2, ..., hT ] that
the Bi-LSTM layer produces, where T is the input length. w
is a trained weight vector and wT is a transpose.
C. Claim History Representation
Given the encounter vectors vei output by the Encounter
Representation layer for every encounter ei in a claim histor,
now we discuss how to generate vector for each patient’s claim
history.
One intuitive way is to use a LSTM model on the sequence
of encounter vectors to generate a claim history vector. Indeed
the sequential order of encounter indicate the temporal order
of the encounter events. However, LSTM does not capture the
time differences among the encounters. Referring to Figure
3. The first two encounters are 7 days apart, with the second
encounter being a follow-up visit of a surgery preformed in
the first encounter. The time between the second and the third
encounter is 9 months, with the third encounter being a visit
to a primary care doctor for a flu. As we can see from this
example, two adjacent encounters that has a small time lap
often refer to closely related medical issues. On the other
hand, two adjacent encounters that are a long time apart likely
refer to unrelated medical issues. In this case, the previous
encounter has less importance to the semantics of the current
encounter. Thus, sequential order itself is inadequate to capture
the relationship between encounters, we should also consider
the actual time differences.
We propose to use a Time-aware LSTM (TLSTM) [34] to
generate a claim history vector from the sequence of encounter
vectors for each patient. For each encounter, we consider
not only its claims code, but also its timestamp. The major
component of the TLSTM layer is the subspace decomposition
applied on the memory of the previous time step. The short-
term memory is adjusted proportionally to the amount of time
span between two patient encounters.
g(∆i) = 1/∆i (7)
'POS-11', 'ICD10DX-I10', 'ICD10DX-E109', 
'ICD10DX-E782', 'CPT-99213'
'CPT-92083', 'ICD10DX-H02831', 
'POS-11', 'ICD10DX-H02834'
Encounter 1 Encounter i
'POS-11', 'ICD10DX-I10', 'ICD10DX-
E109', 'ICD10DX-E782', 'CPT-99213'
'CPT-92083', 'ICD10DX-H02831', 
'POS-11', 'ICD10DX-H02834'
Code Attention
…… 
Code Attention
…… 
TLSTM
...
...
Encounter Attention
Patient claim 
history
Sequence of claim 
codes
Bi-LSTM layer
Claim code 
attention
 Encounter vector 
TLSTM layer
Encounter attention
Output layer
Encounter 2
TLSTM TLSTM TLSTMTLSTM
1 2 3
LSTM LSTM LSTMLSTM...
LSTM LSTM LSTMLSTM...
LSTM LSTM LSTMLSTM...
LSTM LSTM LSTMLSTM...
Fig. 5. Architecture Overview of HTNNR
cˆi−1 = ci−1 ∗ g(∆i) (8)
c∗i−1 = c
L
i−1 + cˆi−1 (9)
Here ∆i is the time span between encounter ei and encounter
ei−1, ci−1 is short memory in LSTM, cˆi−1 is the adjusted short
memory by considering time span. c∗i−1 is the final adjusted
previous memory that combines the normal long term memory
cLi−1 and the adjusted short term memory. As we can see, if
the gap between encounter ei and ei−1 is large, which means
there is no new information recorded for the patient for a long
time, the dependence on the short-term memory does not play
a significant role in the prediction of the current output.
In this way, the final cell state in Equation 1 is changed to:
ci = fi  c∗i−1 + Ii  tanh(Wc[Fi, hi−1] + bc) (10)
The patient claim history vectors are calculated from en-
counter vectors as the following:
hi = TLSTM(vei ,∆i), i ∈ [1,M ] (11)
Here vei is the encounter representation for encounter ei,
M is the number of encounters before the target drug taken.
∆i is the elapsed time between encounter ei and ei−1.
Finally the patient claim history vector is fed into an atten-
tion layer to learn the importance of different encounters to
make the prediction whether the target patient will experience
a target ADE.
VI. EXPERIMENT
We implemented the proposed method, referred as HTNNR.
We have conducted extensive experiments to empirically eval-
uate the HTNNR model using real-life claims data. We start
with discussing the model implementation, evaluation setting
and comparison methods. Then we present the empirical
evaluation results.
A. System Implementation
HTNNR is implemented using Python and the Hierarchical
Attention model is implemented using Keras with Tensorflow
backend. The experiments are run on a 20-core computer
server. Existing work indicates that a large batch size may
alleviate the impact of noisy data, while a small size sometimes
can accelerate of convergence [35]. We varied the batch size in
experiments, and set the training batch size to 256 considering
the trade-off of performance and the consumption of training
time and memory. To train ADE classification, we use binary
cross-entropy as the loss function. The optimizer we adopted is
Adaptive Moment Estimation (Adam) which can achieve fast
gradient descent [36]. We use validation-based early stopping
to obtain the models that work the best with the validation
data. The model with the minimum validation error are saved
and used to make prediction the testing data.
B. Evaluation Setting
The data we used is provided by Inovalon. Inovalon’s
MORE2 Registry dataset contains 500K patients. Each pa-
tient contains a sequence of encounters and each encounter
contains a sequence of claim codes, with statistics presented
in Section III-A.
target Drugs. We evaluated our proposed methods on 10
randomly selected drugs among all drugs, each of which has
been taken by more than 20K patients in the dataset. Table III
shows the GPI, description and the number of patients taking
the drug.
TABLE III
TARGET DRUGS
Drug GPI code Description Patient Population
GPI-5818002510 Duloxetine HCl 22616
GPI-3610003000 Lisinopril 124716
GPI-4927006000 Omeprazole 138152
GPI-3400000310 Amlodipine Besylate 127326
GPI-4220003230 Fluticasone Propionate 106106
GPI-3320003010 Metoprolol Tartrate 75561
GPI-3615004020 Losartan Potassium 75570
GPI-5710001000 Alprazolam 44214
GPI-5816007010 Sertraline HCl 39258
GPI-6420001000 Acetaminophen 20618
target ADEs. ADEs are prevalent, and are not totally avoid-
able. The evaluation is performed on target ADEs that are
severe. Table IV shows the target ADE list used in evaluation,
selected based on its severity according to existing studies
[37] and their occurrence in our data set. Here the occurrence
means the number of the patients experienced this ADE in our
data set. Other ADEs can also be used in evaluation.
Training and Testing Data. For each target drug, we extract
all the patients whose claim history contains the GPI code of
the drug. For each patient, we extract the claim history before
taking the target drug. Then we identify the occurrence of
a target ADEs within 3 months after the drug taking using
the method discussed in Section III to generate the label
for this instance. We split all the patients in each drug into
training/testing/validation dataset with ratio 0.7/0.2/0.1. The
final result is the averaged result of these 10 drugs
C. Comparison Methods
Since we are the only study that uses claims history for
personalized ADE risk prediction, there is no existing work to
compare. We use several baseline approaches for comparison.
• Long Short Term Memory (LSTM): This is the method
discussed in Section IV.
TABLE IV
TARGET ADVERSE DRUG EVENTS (ADES)
ADE code (ICD 10) Description
L29.9 Pruritis
K27.9 Stomach or intestinal ulcers
L50.9 Urticaria
T78.40 Allergic Reaction
F329 Depression
R06.00 Dyspnea
D649 Anemia
D696 Thrombocytopenia
M25.50 Arthralgia
R00.2 Palpitation
R20.2 Paresthesia
F419 Anxiety
M79.1 Myalgia
I47.2 Ventricular tachycardia
I63.0 Anorexia
TABLE V
EVALUATION OF OVERALL EFFECTIVENESS
Systems Accuracy Precision Recall AUC
Random Forest 0.78 0.65 0.21 0.75
XGBoost 0.80 0.67 0.25 0.76
LSTM 0.84 0.69 0.34 0.81
CNN 0.83 0.60 0.37 0.80
HTNNR 0.88 0.84 0.51 0.89
• Convolutional Neural Network (CNN): This replaces
the LSTM model in the method discussed in Section IV
with a CNN model. CNN has proven effectiveness in
computer vision [38], natural language processing [39]
• Random Forest: Random forest is a classification algo-
rithm consisting of many decisions trees [40].
• XGBoost: XGBoost is an implementation of gradient
boosted decision tree algorithm which has been widely
used in many classification tasks like emotion analysis
[41] and image classification [42]
Note that every method is trained on the patients for each
target drug independently. For Random Forest and XGBoost,
we use Term Frequency (TF)-Inverse Document Frequency
(IDF) vectors extracted from claim code sequence as features.
TF-IDF has been commonly used as features in text classifi-
cation tasks [43].
D. Evaluation of Overall Effectiveness
Table V shows the performance of different methods on
target drugs. For each system, each number is the average
performance on ten drugs in each drug group.Several obser-
vations can be made.
The proposed HTNNR method consistently achieves the
best performance among these methods on all metrics. One
reason is that the hierarchical attention model to differentiate
the relationship of claim codes in an encounter, and the
relationship of encounters in an claim history. It further uses
different neural networks, Bi-LSTM, and TLSTM, respec-
tively, to capture their different characteristics. On the other
hand, comparison systems model the input as a sequence of
claims code for each patient. Furthermore, the attention layer
in HTNNR gives higher weights on important claim codes and
important encounters.
We also observe that the performance differences on pre-
cision and recall are much bigger than those on AUC and
Accuracy. It is relatively easy for a model to perform well
on AUC and Accuracy on imbalanced data. AUC represents
the model overall classification ability on various thresholds.
It does not reflect well the effect of minority class. Even
if a method mis-classifies most or all of the minority class,
its AUC value can still be high. Similarly, for imbalanced
data, if a model always predicts the majority label, it will
obtain a good accuracy. In our case, the target drug list
has about 80% negative labels. Thus most methods perform
similarly on AUC and Accuracy. High AUC and Accuracy can
be misleading in some imbalanced data. On the other hand,
achieve high precision and recall are much more challenging.
In the following, we focus the analysis on precision and recall.
E. Evaluation on single drug
Table V shows the average results on the 10 drugs. Now
we zoom in to a single drug. We randomly select a drug
from target durg list, GPI-3320003010, and evaluate the per-
formance of comparison systems, and HTNNR on its ADE
risk prediction, as shown in Figure 6. Here we only show
the precision and recall, as the performance differences of
Accuracy and AUC are similar as the result represented in
Table V. There are several things worth mention. First, the
HTNNR model performs better than the comparison systems,
consistent with the evaluation shown in Table V.
we also observe the improvement on recall is higher than
that on precision. Hierarchical framework helps to find more
shared ADE characteristics among the drugs. At the same time,
more noisy information is introduced. Thus, the recall benefits
more from training data from multiple drugs than precision.
Fig. 6. GPI-3320003010 (# of Patients Taken: 75,561)
F. Evaluation of Patient Claim History Length
All the results shown so far takes as input each patient’s
entire medical claim history before taking a target drug to train
each model. To evaluate how the patient claim history impact
the personalized ADE prediction, we evaluated the perfor-
mance on different time length of medical history considered.
Figure 7 shows the performance vary with varying length
of each patient’s medical history used to train HTNNR. The
medical history always ending at the time when a target drug
is recorded in the claim history, with duration count backward.
The results show that using 3 month of claim history generates
better performance than using 1 month of claim history, since
the model can benefit from a larger dataset. After 3 months,
the longer history considered, the better recall, and the worse
precision. The reason is that longer history data can help the
model to find more characteristics of patients and potential
drug interactions, but at the same time, introduce more noisy
information. In a real application, we can adjust the history
length to be considered depends on which metrics is more
important in the application.
Fig. 7. Evaluation on Different Length of Claim History
To summarize, HTNNR achieves the best effectiveness in
all evaluation metrics among all methods tested.
VII. CONCLUSIONS AND FUTURE WORK
In this paper, we studied how to use patient claims history
for personalized ADE risk prediction. We propose the HTNNR
model that captures the characteristics of claim codes and their
relationship. It has a hierarchical framework. The first layer
first generates embedding for claim codes, and then generate
a vector for each encounter using a Bi-LSTM model with an
attention layer. The second layer takes the sequences of en-
counter vectors as input and uses a time-aware neural network
model to generate claim history representation that capture the
temporal order of encounters. The empirical evaluation show
that the proposed HTNNR model is effective and efficient,
especially for rare drugs.
Since claim history is updated on daily basis, as future work
we will investigate how to incrementally train the model based
on the new information available without re-training the model
from scratch every time.
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